Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under article 14-3 of the Pharmaceuticals and Medical Devices Act for emergency use of Moderna’s mRNA COVID-19 vaccine, TAK-919, now known as COVID-19 Vaccine Moderna Intramuscular Injection, in Japan.
Takeda announces approval of Moderna’s COVID-19 vaccine in Japan
May 22, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022